Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
7 studies found for:    Z1071
Show Display Options
Rank Status Study
1 Active, not recruiting Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy;   Procedure: axillary lymph node dissection;   Procedure: neoadjuvant therapy;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: ultrasound imaging
2 Completed
Has Results
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Condition: HIV-1
Interventions: Drug: Maraviroc + Zidovudine/Lamivudine;   Drug: Efavirenz + Zidovudine/Lamivudine;   Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine
3 Terminated DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
Condition: Prostate Cancer
Interventions: Drug: calcitriol;   Drug: docetaxel
4 Active, not recruiting Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010);   Drug: placebo
5 Terminated Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
6 Recruiting Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin;   Drug: Placebo
7 Active, not recruiting Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: SAR339658;   Other: Placebo

Indicates status has not been verified in more than two years